Targeted Cancer Therapy Market: Analysis by Disease Indication; Therapy Type; End-User, Region - Market Size, Industry Dynamics, Opportunity Analysis and Forecast for 2026-2035

The targeted cancer therapy market is experiencing steady and significant growth, with its value estimated at USD 90.89 billion in 2025 and projected to rise to USD 175.48 billion by 2035. This expansion, corresponding to a CAGR of 6.80% from 2026 to 2035, reflects the increasing global adoption of targeted approaches in oncology and the continued shift away from non-specific treatment models toward more individualized cancer care.

A major force behind this growth is the advancement of precision oncology. By tailoring therapies to the molecular and genetic characteristics of specific tumors, precision oncology improves the likelihood of therapeutic success while limiting unnecessary damage to healthy tissues. At the same time, innovations in antibody-drug conjugates (ADCs) are strengthening the market by combining monoclonal antibody targeting with potent cytotoxic payloads, enabling more selective drug delivery directly to tumor cells.

Noteworthy Market Developments

The competitive landscape of the targeted cancer therapy market is shaped by large pharmaceutical companies that are actively expanding their positions through acquisitions, portfolio development, and investment in novel technologies. AstraZeneca has emerged as a dominant force in the antibody-drug conjugate segment, supported by the success of its Enhertu franchise. This position has helped the company establish strong market presence in one of the most dynamic areas of targeted oncology.

Novartis has also strengthened its role in the market by expanding aggressively in radiopharmaceuticals. Its acquisition of MorphoSys for USD 2.9 billion and Mariana Oncology for USD 1.75 billion highlights its strategy of building a stronger targeted oncology pipeline and securing leadership in a rapidly developing therapeutic space. These moves reflect the growing importance of radiopharmaceuticals as a differentiated approach in cancer treatment.

Bristol Myers Squibb made another major strategic move in 2024 through its USD 4.1 billion acquisition of RayzeBio. This transaction gave the company a position in actinium-based therapies, an area of targeted oncology that uses radioactive isotopes to deliver potent therapeutic effects directly to tumor cells. These developments collectively illustrate the increasing strategic intensity and acquisition-driven competition defining the market.

Core Growth Drivers

The most important driver of the targeted cancer therapy market is the increasing incidence of cancer worldwide. As cancer prevalence rises due to aging populations, lifestyle changes, and environmental influences, the need for effective and differentiated treatment options continues to grow. Healthcare providers and patients are increasingly seeking therapies that can improve survival outcomes without causing the extensive toxicity associated with conventional chemotherapy.

This demand is being reinforced by the broader acceptance of targeted treatment models that offer better precision and tolerability. By focusing on specific biological pathways and tumor markers, targeted cancer therapies provide a more refined therapeutic approach, which is supporting their growing use across multiple cancer indications.

Emerging Opportunity Trends

Targeted cancer therapy represents a major evolution in oncology, shifting treatment away from the broad and non-specific mechanism of traditional chemotherapy toward a more precise precision medicine model. Conventional chemotherapy attacks rapidly dividing cells throughout the body, including healthy cells in the gastrointestinal tract, hair follicles, and bone marrow, which leads to substantial systemic toxicity and side effects.

By contrast, targeted therapies are designed to act on specific molecular drivers of cancer, creating opportunities for more effective and individualized treatment. This transition toward precision medicine is a major opportunity trend in the market because it supports better patient outcomes, improved quality of life, and broader acceptance of therapies that are both more selective and clinically sophisticated.

Barriers to Optimization

The high cost of targeted therapies remains one of the most significant barriers to optimization in the targeted cancer therapy market. Some treatments are priced at more than $900,000 per therapy, reflecting the complexity of development, manufacturing, and administration. These costs create serious accessibility challenges, particularly in low-to middle-income countries where healthcare systems often lack the resources to support broad adoption.

Limited insurance coverage and constrained healthcare budgets in these regions further restrict access to advanced therapies. As a result, many patients remain unable to benefit from cutting-edge treatment options despite their clinical potential. This affordability challenge continues to limit market penetration and may slow wider global expansion of targeted cancer therapies.

Detailed Market Segmentation

Based on Therapy Type, Monoclonal Antibodies are expected to hold a leading position in the targeted cancer therapy market, generating more than 43% of total revenue. Their dominance is supported by their broad biological versatility, which allows them to function not only as direct inhibitors of specific cancer markers but also as immune checkpoint inhibitors and highly effective delivery vehicles for cytotoxic payloads. This multifunctional role has made Monoclonal Antibodies central to the development of modern targeted oncology treatment strategies.

Based on Disease Indication, Lung Cancer accounts for more than 32% of total market share, making it the leading disease segment. This dominance reflects the significant global burden of lung cancer, which remains the leading cause of cancer-related mortality and accounts for approximately 18.7% of all cancer deaths. The high clinical urgency surrounding lung cancer continues to drive demand for more effective and targeted treatment options.

Based on End-User, Hospitals represent the largest segment, accounting for 58% of the market. Their leading role is driven by the infrastructure required to manage high-value biologics and administer specialized infusion protocols. Hospital settings are particularly important for supportive care biologics such as Infliximab, which contributes to 32% of overall biosimilar revenue and underscores the financial and clinical significance of hospital-based treatment delivery.

Segment Breakdown

By Disease Indication

• Colorectal Cancer
• Breast Cancer
• Gastrointestinal
• Lung Cancer
• Others

By Therapy Type

• Signal Transduction Inhibitors
• Monoclonal Antibodies
• Small Molecule Inhibitors
• Hormone Therapies
• Others

By End-User

• Cancer and Radiation Therapy Centers
• Hospitals
• Clinics

By Region

• North America
• Europe
• Asia-Pacific
• Middle East and Africa
• South America

Geographical Breakdown

North America holds a leading 39% share of the targeted cancer therapy market, supported largely by the favorable regulatory landscape in the United States. In 2024, the U.S. Food and Drug Administration approved 15 oncology drugs, highlighting a strong innovation pipeline and creating a supportive environment for rapid commercialization. This regulatory momentum has increased confidence among pharmaceutical companies and investors, encouraging continued expansion in the region.

Major industry players have taken advantage of this environment through strategic investments and acquisitions. Bristol Myers Squibb’s USD 4.1 billion acquisition of RayzeBio is a notable example, aimed at securing radiopharmaceutical assets within the United States. This move not only strengthens its oncology portfolio but also reflects the strategic importance of consolidating advanced therapeutic capabilities in North America, reinforcing the region’s leadership in the targeted cancer therapy market.

Leading Market Participants

• Agenus, Inc.
• Amgen, Inc.
• Arcus Biosciences, Inc.
• AstraZeneca Plc.
• Aurinia Pharmaceuticals Inc.
• Celdara Medical LLC
• F. Hoffmann-La Roche & Co.
• Genentech, Inc.
• Gilead Sciences, Inc.
• Nektar Therapeutics Inc.
• Pfizer, Inc.
• Serena Therapeutics Inc.
• Other Prominent Players